Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Acute Myeloid LeukemiaStem Cell Leukemia
Interventions
DRUG

Nalbuphine

"Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."

DRUG

Morphine

"morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."

Trial Locations (1)

Unknown

CCHE, Cairo

All Listed Sponsors
lead

Children's Cancer Hospital Egypt 57357

OTHER

NCT03825887 - Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients | Biotech Hunter | Biotech Hunter